{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:35:26Z","timestamp":1794951326847,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ocala Royal Dames for Cancer Research The Jayne Koskinas Ted Giovanis Foundation for Health and Policy"},{"name":"Ocala Royal Dames for Cancer Research, Inc. The Jayne and Ted Giovanis Foundation for Health and Policy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Intermittent androgen deprivation therapy (IADT) is an attractive treatment for biochemically recurrent prostate cancer (PCa), whereby cycling treatment on and off can reduce cumulative dose and limit toxicities. We simulate prostate-specific antigen (PSA) dynamics, with enrichment of PCa stem-like cell (PCaSC) during treatment as a plausible mechanism of resistance evolution. Simulated PCaSC proliferation patterns correlate with longitudinal serum PSA measurements in 70 PCa patients. Learning dynamics from each treatment cycle in a leave-one-out study, model simulations predict patient-specific evolution of resistance with an overall accuracy of 89% (sensitivity\u2009=\u200973%, specificity\u2009=\u200991%). Previous studies have shown a benefit of concurrent therapies with ADT in both low- and high-volume metastatic hormone-sensitive PCa. Model simulations based on response dynamics from the first IADT cycle identify patients who would benefit from concurrent docetaxel, demonstrating the feasibility and potential value of adaptive clinical trials guided by patient-specific mathematical models of intratumoral evolutionary dynamics.<\/jats:p>","DOI":"10.1038\/s41467-020-15424-4","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T10:03:56Z","timestamp":1586426636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1759-8283","authenticated-orcid":false,"given":"Renee","family":"Brady-Nicholls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis A.","family":"Gerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9781-4494","authenticated-orcid":false,"given":"Andrew Z.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Gatenby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9696-6410","authenticated-orcid":false,"given":"Heiko","family":"Enderling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,9]]},"reference":[{"key":"15424_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7\u201334 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"15424_CR2","doi-asserted-by":"crossref","unstructured":"Fizazi K., et al. LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. J Clin Oncol 35, LBA3-LBA3 (2017).","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA3"},{"key":"15424_CR3","doi-asserted-by":"crossref","unstructured":"Zhang J., Cunningham J. J., Brown J. S., Gatenby R. A. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat. Commun. 8, 1816 (2017).","DOI":"10.1038\/s41467-017-01968-5"},{"key":"15424_CR4","doi-asserted-by":"publisher","first-page":"19914","DOI":"10.1073\/pnas.0707766104","volume":"104","author":"AR Wargo","year":"2007","unstructured":"Wargo, A. R., Huijben, S., de Roode, J. C., Shepherd, J. & Read, A. F. Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model. Proc. Natl. Acad. Sci. USA 104, 19914\u201319919 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"15424_CR5","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1201546","volume":"367","author":"JM Crook","year":"2012","unstructured":"Crook, J. M. et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N. Engl. J. Med 367, 895\u2013903 (2012).","journal-title":"N. Engl. J. Med"},{"key":"15424_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3390\/app6110352","volume":"6","author":"J Baez","year":"2016","unstructured":"Baez, J. & Kuang, Y. Mathematical models of androgen resistance in prostate cancer patients under intermittent androgen suppression therapy. Appl. Sci. 6, 352 (2016).","journal-title":"Appl. Sci."},{"key":"15424_CR7","doi-asserted-by":"crossref","unstructured":"Cunningham J. J., Brown J. S., Gatenby R. A., Stankova K. Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer. J. Theor. Biol. 459, 67\u201378 (2018).","DOI":"10.1016\/j.jtbi.2018.09.022"},{"key":"15424_CR8","doi-asserted-by":"crossref","unstructured":"Hirata Y., et al. Intermittent androgen suppression: estimating parameters for individual patients based on initial PSA data in response to androgen deprivation therapy. PLoS ONE 10, e0130372 (2015).","DOI":"10.1371\/journal.pone.0130372"},{"key":"15424_CR9","doi-asserted-by":"crossref","unstructured":"Hirata Y., Morino K., Akakura K., Higano C. S., Aihara K. Personalizing androgen suppression for prostate cancer using mathematical modeling. Sci. Rep. 8, 2673 (2018).","DOI":"10.1038\/s41598-018-20788-1"},{"key":"15424_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jtbi.2010.02.027","volume":"264","author":"Y Hirata","year":"2010","unstructured":"Hirata, Y., Bruchovsky, N. & Aihara, K. Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer. J. Theor. Biol. 264, 517\u2013527 (2010).","journal-title":"J. Theor. Biol."},{"key":"15424_CR11","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00332-008-9031-0","volume":"18","author":"AM Ideta","year":"2008","unstructured":"Ideta, A. M., Tanaka, G., Takeuchi, T. & Aihara, Z. A mathematical model of intermittent androgen suppression for prostate cancer. J. Nonlinear Sci. 18, 593\u2013614 (2008).","journal-title":"J. Nonlinear Sci."},{"key":"15424_CR12","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1158\/0008-5472.CAN-13-3162","volume":"74","author":"JD Morken","year":"2014","unstructured":"Morken, J. D., Packer, A., Everett, R. A., Nagy, J. D. & Kuang, Y. Mechanisms of resistance to intermittent androgen deprivation in patients with prostate cancer identified by a novel computational method. Cancer Res. 74, 3673\u20133683 (2014).","journal-title":"Cancer Res."},{"key":"15424_CR13","doi-asserted-by":"crossref","unstructured":"Portz T., Kuang, Y., Nagy, J. A clinical data validated mathematical model of prostate cancer growth under intermittent androgen suppression therapy AIP Advances 2, 0110022 (2012).","DOI":"10.1063\/1.3697848"},{"key":"15424_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/pros.23099","volume":"76","author":"M Elishmereni","year":"2016","unstructured":"Elishmereni, M. et al. Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data. Prostate 76, 48\u201357 (2016).","journal-title":"Prostate"},{"key":"15424_CR15","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.ejca.2006.01.037","volume":"42","author":"AT Collins","year":"2006","unstructured":"Collins, A. T. & Maitland, N. J. Prostate cancer stem cells. Eur. J. Cancer 42, 1213\u20131218 (2006).","journal-title":"Eur. J. Cancer"},{"key":"15424_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1039\/C4IB00191E","volume":"7","author":"H Enderling","year":"2015","unstructured":"Enderling, H. Cancer stem cells: small subpopulation or evolving fraction? Integr. Biol. 7, 14\u201323 (2015).","journal-title":"Integr. Biol."},{"key":"15424_CR17","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1200\/JCO.2007.15.1472","volume":"26","author":"NJ Maitland","year":"2008","unstructured":"Maitland, N. J. & Collins, A. T. Prostate cancer stem cells: a new target for therapy. J. Clin. Oncol. 26, 2862\u20132870 (2008).","journal-title":"J. Clin. Oncol."},{"key":"15424_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/pros.2990150506","volume":"2","author":"JT Isaacs","year":"1989","unstructured":"Isaacs, J. T. & Coffey, D. S. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl. 2, 33\u201350 (1989).","journal-title":"Prostate Suppl."},{"key":"15424_CR19","doi-asserted-by":"publisher","first-page":"10946","DOI":"10.1158\/0008-5472.CAN-05-2018","volume":"65","author":"AT Collins","year":"2005","unstructured":"Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J. & Maitland, N. J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65, 10946\u201310951 (2005).","journal-title":"Cancer Res"},{"key":"15424_CR20","first-page":"2275","volume":"50","author":"N Bruchovsky","year":"1990","unstructured":"Bruchovsky, N., Rennie, P. S., Coldman, A. J., Goldenberg, S. L., To M & Lawson, D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 50, 2275\u20132282 (1990).","journal-title":"Cancer Res."},{"key":"15424_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jmcb\/mjs042","volume":"5","author":"SO Lee","year":"2013","unstructured":"Lee, S. O. et al. New therapy targeting differential androgen receptor signaling in prostate cancer stem\/progenitor vs. non-stem\/progenitor cells. J. Mol. Cell Biol. 5, 14\u201326 (2013).","journal-title":"J. Mol. Cell Biol."},{"key":"15424_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/cncr.21989","volume":"107","author":"N Bruchovsky","year":"2006","unstructured":"Bruchovsky, N. et al. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters. Cancer 107, 389\u2013395 (2006).","journal-title":"Cancer"},{"key":"15424_CR23","doi-asserted-by":"crossref","unstructured":"Baxter W. C., Stanley J. S., Zhang Q., Smith W. D. Developing artificial neural network models of water treatment processes: a guide for utilities. J. Environ. Eng. Sci. 1, 201\u2013211 (2002).","DOI":"10.1139\/s02-014"},{"key":"15424_CR24","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.4161\/cc.9.19.13205","volume":"9","author":"CH Johnson","year":"2010","unstructured":"Johnson, C. H. Circadian clocks and cell division: what\u2019s the pacemaker? Cell Cycle 9, 3864\u20133873 (2010).","journal-title":"Cell Cycle"},{"key":"15424_CR25","doi-asserted-by":"crossref","unstructured":"Fawcett T. An introduction to ROC analysis. Pattern Recognit. Lett. 27, 861\u2013874 (2005).","DOI":"10.1016\/j.patrec.2005.10.010"},{"key":"15424_CR26","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","volume":"368","author":"M Hussain","year":"2013","unstructured":"Hussain, M. et al. Intermittent versus continuous androgen deprivation in prostate cancer. N. Engl. J. Med. 368, 1314\u20131325 (2013).","journal-title":"N. Engl. J. Med."},{"key":"15424_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi, K. N. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 381, 13\u201324 (2019).","journal-title":"N. Engl. J. Med."},{"key":"15424_CR28","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","volume":"76","author":"AP Hoyle","year":"2019","unstructured":"Hoyle, A. P. et al. Abiraterone in \u201chigh-\u201c and \u201clow-risk\u201d metastatic hormone-sensitive prostate cancer. Eur. Urol. 76, 719\u2013728 (2019).","journal-title":"Eur. Urol."},{"key":"15424_CR29","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James, N. D. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387, 1163\u20131177 (2016).","journal-title":"Lancet"},{"key":"15424_CR30","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos, C. E. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J. Clin. Oncol. 36, 1080\u20131087 (2018).","journal-title":"J. Clin. Oncol."},{"key":"15424_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","volume":"17","author":"CL Vale","year":"2016","unstructured":"Vale, C. L. et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 17, 243\u2013256 (2016).","journal-title":"Lancet Oncol."},{"key":"15424_CR32","first-page":"5821","volume":"63","author":"SK Singh","year":"2003","unstructured":"Singh, S. K. et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821\u20135828 (2003).","journal-title":"Cancer Res."},{"key":"15424_CR33","doi-asserted-by":"crossref","unstructured":"Boerrigter E., Groen L. N., Van Erp N. P., Verhaegh G. W., Schalken J. A. Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. Expert. Rev. Mol. Diagn. 20, 219\u2013230 (2020).","DOI":"10.1080\/14737159.2019.1675515"},{"key":"15424_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/jamaoncol.2018.3395","volume":"5","author":"K Stankova","year":"2019","unstructured":"Stankova, K., Brown, J. S., Dalton, W. S. & Gatenby, R. A. Optimizing cancer treatment using game theory: a review. JAMA Oncol. 5, 96\u2013103 (2019).","journal-title":"JAMA Oncol."},{"key":"15424_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","volume":"70","author":"G Gravis","year":"2016","unstructured":"Gravis, G. et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur. Urol. 70, 256\u2013262 (2016).","journal-title":"Eur. Urol."},{"key":"15424_CR36","doi-asserted-by":"crossref","unstructured":"Brady R., Enderling H. Mathematical models of cancer: when to predict novel therapies, and when not to. Bull. Math Biol. 81, 3722\u20133731 (2019).","DOI":"10.1007\/s11538-019-00640-x"},{"key":"15424_CR37","doi-asserted-by":"publisher","first-page":"358","DOI":"10.4111\/kju.2010.51.5.358","volume":"51","author":"DK Lee","year":"2010","unstructured":"Lee, D. K. et al. Progression of prostate cancer despite an extremely low serum level of prostate-specific antigen. Korean J. Urol. 51, 358\u2013361 (2010).","journal-title":"Korean J. Urol."},{"key":"15424_CR38","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1056\/NEJMoa031918","volume":"350","author":"IM Thompson","year":"2004","unstructured":"Thompson, I. M. et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N. Engl. J. Med. 350, 2239\u20132246 (2004).","journal-title":"N. Engl. J. Med."},{"key":"15424_CR39","doi-asserted-by":"publisher","first-page":"7053","DOI":"10.1158\/1078-0432.CCR-07-1506","volume":"13","author":"DC Danila","year":"2007","unstructured":"Danila, D. C. et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res 13, 7053\u20137058 (2007).","journal-title":"Clin. Cancer Res"},{"key":"15424_CR40","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/j.clgc.2015.04.003","volume":"13","author":"JB Aragon-Ching","year":"2015","unstructured":"Aragon-Ching, J. B. et al. Circulating tumor cells in biochemical recurrence of prostate cancer. Clin. Genitourin. Cancer 13, e341\u2013e345 (2015).","journal-title":"Clin. Genitourin. Cancer"},{"key":"15424_CR41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.clgc.2012.01.002","volume":"10","author":"SM Tu","year":"2012","unstructured":"Tu, S. M. & Lin, S. H. Prostate cancer stem cells. Clin. Genitourin. Cancer 10, 69\u201376 (2012).","journal-title":"Clin. Genitourin. Cancer"},{"key":"15424_CR42","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/35065745","volume":"410","author":"L Glass","year":"2001","unstructured":"Glass, L. Synchronization and rhythmic processes in physiology. Nature 410, 277\u2013284 (2001).","journal-title":"Nature"},{"key":"15424_CR43","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.molcel.2016.10.015","volume":"64","author":"T Matsu-Ura","year":"2016","unstructured":"Matsu-Ura, T. et al. Intercellular coupling of the cell cycle and circadian clock in adult stem cell culture. Mol. Cell 64, 900\u2013912 (2016).","journal-title":"Mol. Cell"},{"key":"15424_CR44","doi-asserted-by":"crossref","unstructured":"Banks H. T., Tran H. T. Mathematical and Experimental Modeling of Physical and Biological Processes. Chapman and Hall (2009).","DOI":"10.1201\/b17175"},{"key":"15424_CR45","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00285-012-0535-8","volume":"67","author":"MS Olufsen","year":"2013","unstructured":"Olufsen, M. S. & Ottesen, J. T. A practical approach to parameter estimation applied to model predicting heart rate regulation. J. Math. Biol. 67, 39\u201368 (2013).","journal-title":"J. Math. Biol."},{"key":"15424_CR46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11721-007-0002-0","volume":"1","author":"R Poli","year":"2007","unstructured":"Poli, R., Kennedy, J. & Blackwell, T. Particle swarm optimization. Swarm Intell. 1, 33 (2007).","journal-title":"Swarm Intell."},{"key":"15424_CR47","doi-asserted-by":"crossref","unstructured":"Jaworska D., Szliszka E. Targeting apoptotic activity against prostate cancer stem cells. Int. J. Mol. Sci. 18, pii: E1648 (2017).","DOI":"10.3390\/ijms18081648"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-15424-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-15424-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-15424-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T20:21:18Z","timestamp":1670271678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-15424-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,9]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["15424"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-15424-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,9]]},"assertion":[{"value":"9 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Provisional patent application entitled \u201cMethods for PCa intermittent adaptive therapy\u201d. Applicants\/inventors: Renee Brady-Nicholls, Heiko Enderling; application number: 62\/944.804; status: provisionally filed. The patent covers methods related to using the mathematical model to adjust an individual patient\u2019s treatment administration (both timing and alternative treatment options), thereby increasing TTP. T.Z.: Research funding: Acerta, Novartis, Merrimack, Abbvie\/StemCentrx, Merck, Regeneron, Mirati Therapeutics, Janssen, Astra Zeneca, Pfizer, OmniSeq, Personal Genome Diagnostics, Seattle Genetics; Speakers Bureau: Genentech\/Roche, Exelixis, Sanofi-Aventis, Genomic Health; Advisory Board: Genentech\/Roche, Merck, Exelixis, Sanofi-Aaventis, Janssen, Astra Zeneca, Pfizer, Amgen, BMS, Pharmacyclics, Seattle Genetics, Bayer; Consultant: Bayer, Astra Zeneca, Foundation Medicine; Employee: Capio Biosciences, Archimmune Therapeutics (spouse); Stockholder: Capio Biosciences, Archimmune Therapeutics (spouse); A.Z.W.: Cofounder, stockholder and consultant: Capio Biosciences, Archimmune Therapeutics; J.Z.: Consultant: Dendreon, Advisory Board: AstraZeneca, Bayer, Clovis Oncology, Seattle Genetics, Speaker Bureau: Merck, Sanofi. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1750"}}